BAX » Topics » Divestitures and Other

This excerpt taken from the BAX 10-Q filed Aug 9, 2005.

Divestitures and Other

 

Net cash flows relating to divestitures and other totaled $49 million during the first half of 2005 and $31 million in the first half of 2004. The 2005 total principally related to the collection of a loan from Cerus Corporation, a company in which Baxter owns approximately 1% of the common stock, and the cash proceeds relating to the divestiture of the Renal segment’s RTS business in Taiwan. The 2004 total principally related to the sale of a building and the return of collateral.

 

This excerpt taken from the BAX 10-Q filed May 6, 2005.

Divestitures and Other

 

Net cash flows relating to divestitures and other totaled $49 million for the first quarter of 2005 and $26 million for the first quarter of 2004. The 2005 total principally related to the collection of a loan from Cerus Corporation, a company in which Baxter owns approximately 1% of the common stock, and the cash proceeds relating to the divestiture of the Renal segment’s RTS business in Taiwan. The 2004 total principally related to the sale of a building and the return of collateral.

 

21


Table of Contents
This excerpt taken from the BAX 10-Q filed Mar 31, 2005.

Divestitures and Other

 

Net cash flows relating to divestitures and other totaled $26 million in 2004, and principally related to the sale of a building and the return of collateral.

 

18


This excerpt taken from the BAX 10-Q filed Mar 31, 2005.

Divestitures and Other

 

Net cash flows relating to divestitures and other totaled $31 million in the first half of 2004, and principally related to the sale of a building and the return of collateral.

 

This excerpt taken from the BAX 10-Q filed Mar 31, 2005.

Divestitures and Other

 

Net cash flows relating to divestitures and other totaled $31 million in the first nine months of 2004, and principally related to the sale of a building and the return of collateral.

 

This excerpt taken from the BAX 10-K filed Mar 16, 2005.

Divestitures and Other

Net cash flows relating to divestitures and other totaled $26 million in 2004, and primarily related to the sale of a building and the return of collateral.

 

The cash inflows relating to divestitures and other in 2003 primarily consisted of the net cash proceeds relating to the company’s divestiture of its investment in Acambis. The cash inflows relating to divestitures and other in 2002 primarily consisted of $41 million relating to the sales of certain land and facilities, $15 million relating to the transfer of assets to Edwards Lifesciences Corporation, as further discussed in Note 2, and a final cash receipt related to a prior year divestiture in the Medication Delivery segment. These cash inflows in 2002 were partially offset by a payment made to extinguish the company’s liability relating to certain put rights.

 

Cash Flows from Financing Activities

 

This excerpt taken from the BAX 10-K filed Mar 14, 2005.

Divestitures and Other

The cash inflows relating to divestitures and other in 2003 principally consisted of the net cash proceeds relating to the company’s divestiture of its investment in Acambis. The cash inflows relating to divestitures and other in 2002 principally consisted of $41 million relating to the sales of certain land and facilities, $15 million relating to the transfer of assets to Edwards Lifesciences Corporation, as further discussed in Note 2, and a final cash receipt related to a prior year divestiture in the Medication Delivery segment. These cash inflows in 2002 were partially offset by a payment made to extinguish the company’s liability relating to certain put rights. In 2001, the company generated $44 million of cash relating to the sale and leaseback of certain assets.

 

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki